A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE)

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00513370
First received: August 6, 2007
Last updated: April 7, 2011
Last verified: April 2011
  Purpose

To evaluate the safety profile, the effectiveness and the economic impact of adalimumab when used for the treatment of subjects with active plaque psoriasis who have not adequately responded to prior psoriasis therapy.


Condition Intervention Phase
Psoriasis
Biological: Humira (adalimumab)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Canadian Open-Label Access Program to Evaluate the Safety and the Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PASI 75 is a 75% or greater improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree


Secondary Outcome Measures:
  • Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Mean change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree

  • Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Mean percent change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.

  • Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA) [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Number of subjects with improvement on the Physician's Global Assessment for Psoriasis (PGA). The PGA is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject, where 0 = clear and 6 = very severe. Improvement is defined as a reduction in PGA score.

  • Number of Subjects Achieving a Clinical Response Defined as a Physician's Global Assessment for Psoriasis (PGA) of "Clear" or "Clear or Minimal" [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Number of subjects achieving a response of "Clear" or "Clear or Minimal" on the Physician's Global Assessment for Psoriasis. This is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Minimal, 2-Mild, 3-Moderate, 4-severe, 5-very severe.

  • Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Mean Change from Baseline in Physician Global Assessment of Arthritic Disease Activity as measured on a 100-mm visual analog scale where 0 mm = no arthritis activity and 100 mm = extremely active arthritis.

  • Number of Subjects With Psoriasis Area and Severity Index (PASI) 50/75/90/100 Response [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    PASI 50/75/90/100 is a >=50% / >=75% / >=90% / 100% improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.

  • Mean Change From Baseline in Tender Joint Count at 16 and 24 Weeks [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Mean change in the number of tender joints from Baseline. 78 joints were evaluated for tenderness, including all 76 joints evaluated for swelling plus the hip joints.

  • Mean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Mean change in the number of swollen joints from Baseline. 76 joints were evaluated for swelling, corresponding to all joints evaluated for tenderness except for the hip joints.

  • Mean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Mean change in the Patient's Global Assessment of Joint Pain from Baseline, as assessed on a 100-mm visual analog scale where 0 mm = no pain and 100 mm = pain as bad as it could be.

  • Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Mean change in the Dermatology Life Quality Index (DLQI) from Baseline. The questionnaire contains 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired; the minimum clinically important difference is 2.3 to 5.7 point change.

  • Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0 [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Number of subjects achieving a Dermatology Life Quality Index (DLQI) score of 0 (indicating total lack of impairment). The DLQI consists of 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired.

  • Mean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
    Change in the Beck Depression Inventory from Baseline. The BDI-II contains 21 questions and is scored from 0-63; higher scores indicate more severe depression symptoms.

  • Change From Baseline on the EuroQol (EQ-5D) Quality of Life Questionnaire [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
  • Change in Productivity Outcomes and Costs From Baseline as Measured by the Health and Labour Questionnaire (HLQ) [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]
  • Change in Resource Utilization Outcomes and Costs From Baseline as Measured by the Health Care Resource (HCR) Questionnaire [ Time Frame: 16 and 24 weeks ] [ Designated as safety issue: No ]

Enrollment: 203
Study Start Date: September 2007
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Biological: Humira (adalimumab)
Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
Other Names:
  • ABT-D2E7
  • adalimumab
  • Humira

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has a clinical diagnosis of psoriasis for at least 6 months prior to the Screening, as determined by subject interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator
  • Subject must have stable plaque psoriasis for at least 2 months prior to the Screening, as determined by subject interview of his/her medical history
  • Subject has moderate to severely active plaque psoriasis at Baseline defined as: BSA (Body Surface Area) > 10% and a Psoriasis Area and Severity Index (PASI) > 12
  • Subject has active psoriasis despite treatment with topical agents
  • Subject has failed to respond to, is intolerant to or unable to access phototherapy
  • Subject has failed to respond to, is intolerant to or has contraindication for at least two of the following therapies:

    • CyA (Cyclosporine A)
    • MTX (Methotrexate)
    • Oral retinoid
  • If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control:

    • Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)
    • Contraceptives (oral or parenteral) for three months (90 days) prior to study drug administration
    • A vasectomized partner
    • Total abstinence from sexual intercourse
  • If female and of childbearing potential, the result of a serum pregnancy test performed at Screening is negative
  • Able and willing to self-administer sc injections or has available qualified person(s) to administer sc injections
  • Able and willing to give written informed consent and comply with the requirements of the study protocol

Exclusion Criteria:

  • Subject has other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with the evaluation of psoriasis or compromise the subject's safety
  • Subject has erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis as the primary morphology of their psoriasis
  • Subject has a history of an allergic reaction or significant sensitivity to constituents of adalimumab
  • Investigational agents not mentioned must be discontinued at least 30 days or 5 half-lives prior to the Baseline visit (whichever is longer)
  • Topical therapies:

    • Subject started receiving a new topical therapy within the last four weeks prior to the Baseline visit for areas other than the palms, soles of feet, axilla and groin.
    • Dose(s) and regimen(s) of topical therapy(ies) that the subject is receiving at the Baseline visit, for areas other than the palms, soles of feet, axilla and groin, was (were) increased during the four weeks that preceded the Baseline visit.
    • Subject is likely to require the initiation of a new topical therapy for the treatment of psoriasis such as corticosteroids, vitamin D analogs, or retinoids during the first 16 weeks that will follow the Baseline visit. (During the first 16 weeks that will follow the Baseline visit, initiation of topical therapies are allowed for the palms, soles of feet, axilla and groin area only).
  • Oral or injectable corticosteroids therapies:

    • Subject started receiving oral or injectable doses of corticosteroids within the last four weeks prior to the Baseline visit.
    • Dose(s) and regimen(s) of corticosteroids therapy(ies) that the subject is receiving at the Baseline visit, was (were) increased during the four weeks that preceded the Baseline visit.
    • Subject is likely to require the initiation of oral or injectable dose of corticosteroids therapies for the treatment of psoriasis during the first 16 weeks that will follow the Baseline visit.
  • Phototherapies

    • Subject started being treated with UVB phototherapy, within the last four weeks prior to the Baseline visit.
    • Regimen(s) of concomitant UVB phototherapy that the subject is receiving at the Baseline visit was (were) increased during the four weeks that preceded the Baseline visit.
    • Subject is likely to require the initiation of UVB therapy during the first 16 weeks that will follow the Baseline visit.
    • Subject was treated with psoralen UVA (PUVA) phototherapy within the last four weeks prior to the Baseline visit.
    • Subject is likely to require PUVA phototherapy during the course of the study.
    • Subject cannot avoid excessive sun exposure or the use of tanning booths for at least 2 weeks prior to Baseline and during the first 16 weeks that will follow the Baseline visit.
  • Systemic Therapies:

    • Subject has been initiated on a new systemic agent for the treatment of psoriasis within the last four weeks prior to the Baseline visit.
    • Dose(s) and regimen(s) of systemic therapy(ies) that the subject is receiving at the Baseline visit, was (were) increased during the four weeks that preceded the Baseline visit.
    • Subject is likely to require the initiation of systemic therapy, other than adalimumab, for the treatment of psoriasis during the first 16 weeks that will follow the Baseline visit.
    • Subject has been treated with systemic calcineurin inhibitors (cyclosporin, FK506 and others) within the last four weeks prior to the Baseline visit.
    • Subject is likely to receive systemic calcineurin inhibitors during the course of the study.
    • Subject has received Anakinra/Kineret within the last 2 weeks prior to the Baseline visit and is likely to receive Anakinra/Kineret during the course of the study.
  • Subject cannot discontinue the following systemic psoriasis therapies:

    • Alefacept must be discontinued at least 12 weeks prior to the Baseline visit.
    • Efalizumab must be discontinued at least 6 weeks prior to the Baseline visit.
    • Infliximab must be discontinued at least 8 weeks prior to the Baseline visit.
    • Etanercept must be discontinued at least 3 weeks prior to the Baseline visit.
  • Subject has a history of cancer or lymphoproliferative disease other than:

    • Successfully and completely treated Cervical dysplasia, with no recurrence within the last five years.
  • Has a history of uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure, New York Heart Association (NYHA) III, IV, recent stroke (within three months), chronic leg ulcer and any other condition (e.g., indwelling urinary catheter) which, in the opinion of the Investigator, would put the subject at risk by participation in the protocol or who would make the subject unsuitable for the study.
  • Positive serology for hepatitis B indicating acute or chronic infection.
  • Currently taking or likely to begin anti-retroviral therapy at any time during the course of the study.
  • Subject is known to have immune deficiency, history of human immunodeficiency virus (HIV) or is immunocompromised.
  • Persistent or recurrent or severe infections requiring hospitalization or treatment with intra-venous (IV) antibiotics within 30 days, or oral antibiotics within 14 days, prior to Baseline.
  • Female subjects who are pregnant or breastfeeding.
  • Has a history of clinically significant drug or alcohol abuse in the last year.
  • Previous diagnosis or signs of central nervous system demyelinating diseases (e.g., optic neuritis, visual disturbance, gait disorder/ataxia, facial paresis, apraxia).
  • History of active tuberculosis (TB), history of histoplasmosis or listeriosis.
  • Has latent TB (positive purified protein derivative (PPD) skin test, two-step PPD when applicable, and chest X-ray indicative of TB) or has other risk factors for the activation of latent TB, e.g. previous exposure to TB, and has not initiated TB prophylaxis prior to the first adalimumab treatment. In either case, the Abbott Medical Advisor must be contacted before initiating the study treatment.
  • Subjects will be excluded if the CXR is found to have changes suggestive of old healed tuberculous lesion (e.g. calcified nodule, fibrotic scar, apical or basilar pleural thickening etc.).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00513370

Locations
Canada, Alberta
Calgary, Alberta, Canada, T3A 2N1
Calgary, Alberta, Canada, T2S 3B3
Edmonton, Alberta, Canada, T5K 1X3
Canada, British Columbia
Surrey, British Columbia, Canada, V3R 6A7
Vancouver, British Columbia, Canada, V5Z 4E8
Canada, Manitoba
Winnipeg, Manitoba, Canada, R3C 1R4
Winnipeg, Manitoba, Canada, R3C 0N2
Canada, New Brunswick
Moncton, New Brunswick, Canada, E1C 8X3
Canada, Newfoundland and Labrador
St. John's, Newfoundland and Labrador, Canada, A1C 2H5
St. John's, Newfoundland and Labrador, Canada, A1B 3E1
Canada, Nova Scotia
Halifax, Nova Scotia, Canada, B3H 1Z4
Canada, Ontario
Barrie, Ontario, Canada, L4M 6L2
Fenwick, Ontario, Canada, L0S 1C0
Hamilton, Ontario, Canada, L8N 1V6
London, Ontario, Canada, N5X 2P1
London, Ontario, Canada, N6A 3H7
Markham, Ontario, Canada, L3P 1A8
Nepean, Ontario, Canada, K2G 6E2
North Bay, Ontario, Canada, P1B 3Z7
Oakville, Ontario, Canada, L6K 1E1
Oakville, Ontario, Canada, L6J 7W5
Toronto, Ontario, Canada, M4V 1R1
Waterloo, Ontario, Canada, N2J 1C4
Canada, Quebec
Montreal, Quebec, Canada, H3Z 2S6
Sherbrooke, Quebec, Canada, J1H 1Z1
Ste-Foy, Quebec, Canada, G1V 4X7
Canada
Quebec, Canada, G1J 1X7
Sponsors and Collaborators
Abbott
Investigators
Principal Investigator: Kim Papp, MD PhD FRCPC K. Papp Clinical Research Inc.
  More Information

No publications provided

Responsible Party: Isabel Pereira, Affiliate Project Manager, Abbott
ClinicalTrials.gov Identifier: NCT00513370     History of Changes
Other Study ID Numbers: W10-151
Study First Received: August 6, 2007
Results First Received: August 21, 2009
Last Updated: April 7, 2011
Health Authority: Canada: Health Canada

Keywords provided by Abbott:
Psoriasis
adalimumab

Additional relevant MeSH terms:
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014